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SUMMARY
Forty-six allogeneic hematopoietic stem cell transplantation (HSCT) patients were monitored for the presence of CMV antibodies,
CMV-DNA and CMV antigens after transplantation. Immunoenzymatic serological tests were used to detect IgM and the increase
in CMV IgG antibodies (↑IgG), a nested polymerase chain reaction (N-PCR) was used to detect CMV-DNA, and an antigenemia
assay (AGM) was used to detect CMV antigens. The presence of CMV-IgM and/or CMV-↑IgG antibodies was detected in 12/46
(26.1%) patients, with a median time between HSCT and the detection of positive serology of 81.5 days. A positive AGM was
detected in 24/46 (52.2%) patients, with a median time between HSCT and antigen detection of 62 days. Two or more consecutive
positive N-PCR results were detected in 32/46 (69.5%) patients, with a median time between HSCT and the first positive PCR of
50.5 days. These results confirmed that AGM and mainly PCR are superior to serology for the early diagnosis of CMV infection.
Six patients had CMV-IgM and/or CMV-↑IgG with a negative AGM (five cases) or N-PCR assay (one case). In five of these cases
the serological markers were detected during the first 100 days after HSCT, the period of highest risk. These findings support the
idea that serology may be useful for monitoring CMV infections in HSCT patients, especially when PCR is unavailable.
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INTRODUCTION
Several reports have shown that cytomegalovirus (CMV) infection
after hematopoietic stem cell transplantation (HSCT) is associated with
significant morbidity, decreased patient survival, and considerable cost
to health-care systems10,12. In recent years, there have been important
advances in antiviral prophylactic strategies and in the development of
sensitive diagnostic techniques for monitoring recipients of bone
marrow transplantation (BMT)2. Newer methods, such as early CMV
pp65 antigenemia assay and CMV-DNA amplification, can diagnose
CMV infection in its very early period3,14. Serological tests for detecting
specific IgM antibodies and/or a significant increase in specific IgG
concentrations are valuable diagnostic tools in BMT recipients with
primary or recurrent CMV infection4,6.
In this study, we compare the results obtained with a nested polymerase
chain reaction (N-PCR), an antigenemia assay (AGM) and serology
(detection of CMV-IgM antibodies and a significant increase in CMV-
IgG concentrations) obtained during the first four months after HSCT.
MATERIAL AND METHODS
Patients: Forty-six myeloablative HSCT recipients with HLA
identical siblings were selected at the BMT Unit of the University
hospital of the State University of Campinas (UNICAMP). All of the
patients (39 adults and seven children) had hematological malignancies.
The conditioning regimens and acute graft versus host disease (GVHD)
prophylaxis were selected based on ongoing protocols at the university
hospital. All patients received GVHD prophylaxis with cyclosporine
(CSP) and methotrexate (MTX) and received ganciclovir (GCV)
universal prophylaxis at a dose of 5 mg/kg i.v., once daily, three days
per week, from the engraftment until day 75 after transplantation.
Patients were followed from day 0 to day 150 after transplant. The
AGM and N-PCR were done weekly, whereas serology was performed
once a month. This study was approved by the Ethics Committee of
the Faculty of Medical Sciences, UNICAMP, and was done in
accordance with the resolutions of the Brazilian National Ethics
Committee.
Diagnostic techniques: The CMV-AGM assay was done as
previously described16, with some modifications5,11. Briefly, EDTA-
treated blood samples were fractionated by dextran sedimentation
followed by erythrocyte lysis. The granulocytes were then centrifuged
to prepare Cytospin slides (3 x 105 granulocytes per slide). The slides
were air-dried and fixed with formaldehyde, prior to immunostaining
with monoclonal antibodies C10 and C11 (Clonab CMV; Biotest,
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Dreieich, Germany), and then reacted with peroxidase-labeled anti-
mouse conjugate (HRP, Biotest, Dreieich, Germany). CMV-DNA in
blood specimens was detected by nested-PCR using primers described
by DEMMLER et al.3 and SHIBATA et al.14. Briefly, leukocytes
remaining from the CMV-AGM assay were lysed and the DNA was
precipitated. The primers were selected from the MIE region of CMV-
AD169. The size of the PCR amplification products was 159 base pairs.
The same protocol was used to amplify the human β-globin gene
sequence to assess the quality of the extracted DNA. Studies on the
sensitivity of the N-PCR showed that five copies of target DNA could
be detected15. Anti-CMV IgM and IgG antibodies were determined on
a Vidas System using commercial kits from Biolab-Mérieux, according
to the manufacturer’s instructions. A fourfold or greater increase in
IgG concentrations (CMV-↑IgG) was considered significant.
Definitions: Active CMV infection was defined based on one or
both of the following criteria: 1) one or more positive cells in the AGM
assay, 2) two or more consecutive positive N-PCR results. For the
diagnosis of CMV disease, the active infection had to be accompanied
by clinical symptoms and histopathology identifying CMV2.
Ganciclovir prophylaxis: CMV-seronegative patients and donors
and patients with aplastic anemia did not receive ganciclovir
prophylaxis. This strategy was based on an established institutional
protocol. When neutropenia occurred, granulocyte colony-stimulating
factor (G-CSF) was administered until the absolute neutrophil count
was > 500 cells/µL.
Statistical analysis: The sensitivity, specificity, positive and
negative predictive values and diagnostic accuracy were determined
using S-Plus software (Math Soft Inc.).
RESULTS
Table 1 shows the frequencies of positive PCR and AGM assays
and the detection of IgM and/or ↑IgG, as well as the median times
between HSCT and the positive results for these assays in the different
CMV donor/recipient combinations.
Positive PCR and AGM assays and the detection of CMV-IgM or
CMV-↑IgG were observed in 32 (69.5%), 24 (52.2%) and 12 (26.1%)
of the 46 patients monitored, respectively.
The median times between HSCT and positive PCR and AGM
assays and the detection of CMV-IgM or CMV-↑IgG were 50.5 (range
0-143 days), 62 (range 17-133 days), and 81.5 days (range 33-131
days), respectively.
Thirteen patients (11 in the D+/R+ combination, two in the D+/R-
combination) had positive PCR and negative AGM results, whereas 21
patients (15 in the D+/R+ combination, four in the D+/R- combination
and two in the D-/R+ combination) had a positive PCR without detection
of CMV-IgM or CMV-↑IgG. Five patients (four in the D+/R+
combination and one in the D-/R+ combination) had a positive AGM
assay and negative PCR, whereas 17 patients (12 in the D+/R+
combination, two in the D+/R- combination and three in the D-/R+
combination) had a positive AGM assay without detection of CMV-
IgM or CMV-↑IgG.
In the D+/R+ combination, one patient had CMV-↑IgG, a negative
PCR and a positive AGM assay, and five patients had CMV-IgM or
CMV-↑IgG, a positive PCR and a negative AGM.
Two patients in the D+/R+ combination showed CMV-related
gastrointestinal symptoms after HSCT and were successfully treated
with ganciclovir (GCV). In one of these patients, the PCR and AGM
assays became positive at the same time as the onset appearance of the
clinical symptoms, 33 days after HSCT, whereas CMV-IgM was
detected 49 days later. In the other patient, the PCR and AGM assays
became positive 55 days after HSCT and 26 days before the onset of
the clinical symptoms; CMV-IgM was detected 43 days after the PCR
and AGM assays became positive.
Using N-PCR as the reference standard, the AGM assay showed
59.4% sensitivity and 64.3% specificity (positive predictive value =
79.2%; negative predictive value = 64.3%; diagnostic accuracy =
60.9%), whereas the sensitivity and specificity of the serology were
34.4% and 92.9%, respectively (positive predictive value = 91.7%;
negative predictive value = 92.8%; diagnostic accuracy = 52.2%).
DISCUSSION
CMV disease continues to be a major source of patient morbidity
and mortality after HSCT1,8,10. After infection, CMV remains latent in
several cell types and may eventually produce disease. Reactivation of
Table 1
PCR, AGM and serological results for HSCT recipients
CMV N-PCR + MT for a AGM + MT for a Serology + MT for a CMV
serostatus (%) positive (%) positive (%) positive disease
N-PCR after AGM after serology after
HSCT(range) HSCT (range) HSCT (range)
D+/R+ (n=38) 26/38 (68.4) 39.5 (0-143) 19/38 (50) 61.0 (17-131) 12/38 (31.5) 81.5 (33-131) 2/38
D+/R- (n=5) 4/5 (80) 57 (46-88) 2/5 (40) 124 (115-133) 0/5 - 0/5
D-/R+ (n=3) 2/3 (66.6) 61 (54-68) 3/3 (100) 91.3 (61-131) 0/3 - 0/3
Total (n=46) 32/46 (69.5) 50.5 (0-143) 24/46 (52.2) 62 (17-133) 12/46 (26.1) 81.5 (33-131) 2/46
D+ = positive donor; R- = negative recipient; D- = negative donor; R+ = positive recipient; MT = median times (days).
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a latent CMV infection may occur in periods of reduced cellular
immunity, such as with AIDS, or during immunosuppressive therapies,
such as those used after solid organ and bone marrow transplantation8.
Since CMV infections are either asymptomatic or associated with non-
specific clinical manifestations, laboratory techniques are essential for
diagnosing the viral infection. PCR and AGM are considered the most
effective markers for diagnosing active CMV infection in transplant
recipients1,2,5,9-12,14,16. In BMT recipients, the ability of PCR to detect
active CMV infection may be better than that of AGM1,2.
The development of a cellular immune response against CMV
protects the host from dissemination of the virus after reactivation8.
However, CMV-specific antibodies cannot prevent virus reactivation.
Nevertheless, there is evidence that antiviral antibodies have a
modulatory effect on the infection and on the subsequent clinical course
of CMV disease13.
In the present study, 46 myeloablative HSCT recipients with HLA-
identical siblings were followed up weekly in order to evaluate the
incidence of active CMV infections on the basis of CMV PCR, AGM
and serology. Our results confirmed that AGM and mainly PCR are
superior to serology for the early diagnosis of active CMV infection
and improves the chances for implementation specific antiviral
treatment. However, approximately 26% of the patients developed a
humoral immune response to CMV, and this response occurred 33 to
131 days (median = 81.5 days) after transplantation. Six patients had
CMV-IgM and/or CMV-↑IgG with a negative AGM (five cases) or
PCR assay (one case). In five of these cases, the serological markers
were detected during the first 100 days after HSCT, the period of highest
risk. When compared with N-PCR as reference standard test, the
serology test had predictive positive and negative values of 91.7% and
92.8%, respectively.
These findings support the idea that serology may be useful for
monitoring CMV infections in HSCT patients, especially when PCR
is unavailable.
RESUMO
Estudo comparativo entre sorologia, antigenemia e reação em
cadeia da polimerase para o monitoramento da infecção por
citomegalovírus em pacientes receptores de transplantes de
células progenitoras hematopoéticas
Quarenta e seis pacientes receptores de transplantes de células
progenitoras hematopoéticas (TCPH) foram monitorados em relação
à infecção ativa por citomegalovírus (CMV). Testes sorológicos
imunoenzimáticos foram utilizados para a detecção de anticorpos IgM
e elevação significativa das concentrações de anticorpos IgG (↑IgG),
nested-PCR (N-PCR) foi utilizada para a detecção de CMV-DNA e
antigenemia (AGM) para a detecção de antígenos virais. A presença
de CMV-IgM e/ou CMV-↑IgG foi detectada em 12/46 (26,1%)
pacientes, sendo o tempo mediano entre o transplante e a detecção dos
marcadores sorológicos de 81,5 dias; AGM positiva foi detectada em
24/46 (52,2%) pacientes, sendo o tempo mediano entre o transplante e
a detecção de antígenos virais de 62 dias. Dois ou mais resultados
positivos consecutivos de N-PCR foram detectados em 32/46 (69,5%)
pacientes, sendo o tempo mediano entre o transplante e o primeiro
teste positivo de 50,5 dias. Esses resultados confirmaram que a AGM
e principalmente a PCR são superiores à sorologia, com relação ao
diagnóstico da infecção pelo CMV. Seis pacientes apresentaram reações
CMV-IgM positivas e/ou CMV-↑IgG com reações negativas de AGM
(cinco casos) ou N-PCR (um caso). Em cinco desses casos, os
marcadores sorológicos foram detectados nos 100 primeiros dias após
o transplante, considerado o período de maior risco. Esses resultados
indicam que os testes sorológicos podem ser úteis no monitoramento
da infecção por CMV após o transplante de células progenitoras
hematopoéticas, principalmente quando a N-PCR não for disponível.
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